This study will assess different formulations of the modified formulation of VRVg (VRVg 2) to be tested in parallel to the initial VRVg formulation (VRVg 1) and Imovax rabies. Immune responses will be assessed at Day 14, Day 28, Day 42, and at Month 7. Safety events will also be reported.